Official Title: A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma. NCT02159066
Good to see that Novartis runs it.
agreed. and with Merck just taking out Idenix, it could signal the start of buying season for big pharma. There is so much upside with Array, I just can't see them making it more than a year without a buyout.
especially because big pharma has some empty pipelines and full pockets right now.